Trials / Unknown
UnknownNCT05783570
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307
A Dose-escalation, Single-arm, Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 Targeted Chimeric Antigen Receptor T Cell Therapy in Patients With GPC3 Positive Advanced Hepatocellular Carcinoma Who Have Failed Standard Therapy
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Eutilex · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307, Autologous Glypican 3 (GPC3) Targeted Chimeric Antigen Receptor T cell therapy in Patients with GPC3 Positive Advanced Hepatocellular Carcinoma who Have Failed Standard Therapy
Detailed description
A Dose-escalation, Single-arm, Open-Label, Phase 1 Study
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | EU307 CAR-T Cell | * Dose to be administered: a single dose * IV administration * Dosing rate: To be administrated at a rate of approximately 2 mL/min |
Timeline
- Start date
- 2023-08-24
- Primary completion
- 2025-06-01
- Completion
- 2025-12-01
- First posted
- 2023-03-24
- Last updated
- 2024-03-15
Locations
4 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05783570. Inclusion in this directory is not an endorsement.